Davis Matthew R, McCreary Erin K, Pogue Jason M
Department of Clinical Pharmacy, University of California Los Angeles Ronald Reagan Medical Center, Los Angeles, CA, USA.
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Infect Dis Ther. 2020 Sep;9(3):525-536. doi: 10.1007/s40121-020-00318-1. Epub 2020 Jul 10.
Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
瑞德西韦是一种核苷类抗病毒药物，最近在多项治疗新冠肺炎的随机试验中进行了研究。现有的观察性和前瞻性数据相互矛盾，这就要求临床医生审慎评估并协调各项结果，以确定哪些患者群体可能从瑞德西韦治疗中获得最大益处，尤其是在药物供应短缺的情况下。在本综述中，我们分析了2020年1月1日至2020年5月31日期间新冠肺炎患者的瑞德西韦相关临床数据。
